Accelerate Diagnostics Inc (AXDX)

$5.61

+0.33

(+6.25%)▲

Market is closed - opens 7 PM, 25 Sep 2023

Insights on Accelerate Diagnostics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 2.81M → 2.92M (in $), with an average increase of 3.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -15.70M → -25.98M (in $), with an average decrease of 19.6% per quarter

  • Vs SYK

    In the last 1 year, Stryker Corporation has given 37.9% return, outperforming this stock by 103.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 39.2% return, outperforming this stock by 134.3%

Performance

  • $5.29
    $5.75
    $5.61
    downward going graph

    5.7%

    Downside

    Day's Volatility :8.0%

    Upside

    2.43%

    downward going graph
  • $4.50
    $17.80
    $5.61
    downward going graph

    19.79%

    Downside

    52 Weeks Volatility :74.72%

    Upside

    68.48%

    downward going graph

Returns

PeriodAccelerate Diagnostics IncSector (Health Care)Index (Russel 2000)
3 Months
-21.16%
-1.4%
0.0%
6 Months
12.2%
2.2%
2.0%
1 Year
-65.16%
6.0%
5.3%
3 Years
-95.12%
26.3%
19.9%

Highlights

Market Capitalization
80.6M
Book Value
- $2.69
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-7.08
PEG Ratio
-0.55
Wall Street Target Price
9.0
Profit Margin
0.0%
Operating Margin TTM
-493.51%
Return On Assets TTM
-66.26%
Return On Equity TTM
0.0%
Revenue TTM
11.7M
Revenue Per Share TTM
1.19
Quarterly Revenue Growth YOY
-24.3%
Gross Profit TTM
3.3M
EBITDA
-54.4M
Diluted Eps TTM
-7.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.43
EPS Estimate Next Year
-2.65
EPS Estimate Current Quarter
-1.4
EPS Estimate Next Quarter
-1.3

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Accelerate Diagnostics Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 60.43%

Current $5.61
Target $9.00

Company Financials

FY17Y/Y Change
Revenue
4.2M
↑ 1597.97%
Net Income
-64.0M
↓ 3.53%
Net Profit Margin
-1.5K%
↑ 25448.43%
FY18Y/Y Change
Revenue
5.7M
↑ 35.74%
Net Income
-88.3M
↑ 37.95%
Net Profit Margin
-1.6K%
↓ 24.91%
FY19Y/Y Change
Revenue
9.3M
↑ 63.97%
Net Income
-84.3M
↓ 4.55%
Net Profit Margin
-906.8%
↑ 650.98%
FY20Y/Y Change
Revenue
11.2M
↑ 20.09%
Net Income
-78.2M
↓ 7.23%
Net Profit Margin
-700.47%
↑ 206.33%
FY21Y/Y Change
Revenue
11.8M
↑ 5.53%
Net Income
-77.7M
↓ 0.65%
Net Profit Margin
-659.5%
↑ 40.97%
FY22Y/Y Change
Revenue
12.8M
↑ 8.23%
Net Income
-62.5M
↓ 19.57%
Net Profit Margin
-490.06%
↑ 169.44%
Q1 FY22Q/Q Change
Revenue
3.0M
↓ 11.52%
Net Income
-14.2M
↓ 37.79%
Net Profit Margin
-479.55%
↑ 202.56%
Q2 FY22Q/Q Change
Revenue
3.9M
↑ 30.53%
Net Income
-17.8M
↑ 25.51%
Net Profit Margin
-461.1%
↑ 18.45%
Q3 FY22Q/Q Change
Revenue
3.0M
↓ 23.34%
Net Income
-15.7M
↓ 11.78%
Net Profit Margin
-530.57%
↓ 69.47%
Q4 FY22Q/Q Change
Revenue
3.0M
↑ 0.0%
Net Income
-15.9M
↑ 1.22%
Net Profit Margin
-537.03%
↓ 6.46%
Q1 FY23Q/Q Change
Revenue
2.8M
↓ 5.0%
Net Income
-17.9M
↑ 12.9%
Net Profit Margin
-638.19%
↓ 101.16%
Q2 FY23Q/Q Change
Revenue
2.9M
↑ 3.88%
Net Income
-26.0M
↑ 44.77%
Net Profit Margin
-889.42%
↓ 251.23%
FY17Y/Y Change
Total Assets
125.5M
↑ 51.49%
Total Liabilities
6.8M
↑ 35.19%
FY18Y/Y Change
Total Assets
185.3M
↑ 47.61%
Total Liabilities
127.9M
↑ 1778.53%
FY19Y/Y Change
Total Assets
134.4M
↓ 27.44%
Total Liabilities
141.8M
↑ 10.88%
FY20Y/Y Change
Total Assets
93.4M
↓ 30.5%
Total Liabilities
156.2M
↑ 10.18%
FY21Y/Y Change
Total Assets
83.0M
↓ 11.11%
Total Liabilities
118.1M
↓ 24.4%
FY22Y/Y Change
Total Assets
65.0M
↓ 21.71%
Total Liabilities
87.3M
↓ 26.11%
Q1 FY22Q/Q Change
Total Assets
70.4M
↓ 15.28%
Total Liabilities
127.1M
↑ 7.63%
Q2 FY22Q/Q Change
Total Assets
58.7M
↓ 16.53%
Total Liabilities
120.7M
↓ 5.07%
Q3 FY22Q/Q Change
Total Assets
75.8M
↑ 29.15%
Total Liabilities
85.6M
↓ 29.04%
Q4 FY22Q/Q Change
Total Assets
75.8M
↑ 0.0%
Total Liabilities
85.8M
↑ 0.22%
Q2 FY23Q/Q Change
Total Assets
49.9M
-
Total Liabilities
88.5M
-
FY17Y/Y Change
Operating Cash Flow
-55.7M
↑ 4.38%
Investing Cash Flow
-25.7M
↓ 48.1%
Financing Cash Flow
90.4M
↑ 5032.07%
FY18Y/Y Change
Operating Cash Flow
-67.8M
↑ 21.54%
Investing Cash Flow
-20.1M
↓ 21.73%
Financing Cash Flow
125.8M
↑ 39.09%
FY19Y/Y Change
Operating Cash Flow
-64.8M
↓ 4.37%
Investing Cash Flow
52.8M
↓ 362.25%
Financing Cash Flow
6.8M
↓ 94.58%
FY20Y/Y Change
Operating Cash Flow
-50.4M
↓ 22.22%
Investing Cash Flow
13.6M
↓ 74.24%
Financing Cash Flow
11.6M
↑ 70.5%
FY21Y/Y Change
Operating Cash Flow
-47.3M
↓ 6.09%
Investing Cash Flow
8.3M
↓ 38.97%
Financing Cash Flow
43.2M
↑ 271.58%
Q1 FY22Q/Q Change
Operating Cash Flow
-12.6M
↑ 5.52%
Investing Cash Flow
-13.6M
↑ 396.04%
Financing Cash Flow
77.0K
↓ 99.59%
Q2 FY22Q/Q Change
Operating Cash Flow
-13.0M
↑ 3.12%
Investing Cash Flow
4.4M
↓ 132.46%
Financing Cash Flow
-357.0K
↓ 563.64%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.6M
↑ 4.42%
Investing Cash Flow
15.8M
↑ 256.55%
Financing Cash Flow
32.0M
↓ 9073.67%
Q4 FY22Q/Q Change
Operating Cash Flow
-12.6M
↓ 7.12%
Investing Cash Flow
-13.6M
↓ 186.4%
Financing Cash Flow
77.0K
↓ 99.76%
Q2 FY23Q/Q Change
Operating Cash Flow
-10.8M
↓ 19.04%
Investing Cash Flow
915.0K
-
Financing Cash Flow
9.8M
↓ 12835.06%

Technicals Summary

Sell

Neutral

Buy

Accelerate Diagnostics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc
-17.01%
12.2%
-65.16%
-95.12%
-97.51%
Stryker Corporation
Stryker Corporation
2.57%
2.58%
40.35%
39.15%
62.3%
Boston Scientific Corp.
Boston Scientific Corp.
5.59%
10.9%
39.73%
43.55%
38.82%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-8.55%
-13.91%
-16.66%
-10.06%
24.13%
Abbott Laboratories
Abbott Laboratories
-5.82%
-0.31%
-1.69%
-5.12%
35.94%
Medtronic Plc
Medtronic Plc
-2.34%
0.79%
-1.3%
-22.19%
-18.92%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc
NA
NA
-0.55
-6.43
0.0
-0.66
0.0
-2.69
Stryker Corporation
Stryker Corporation
40.29
40.29
2.85
10.36
0.16
0.06
0.01
45.71
Boston Scientific Corp.
Boston Scientific Corp.
89.95
89.95
2.53
1.99
0.05
0.04
0.0
12.46
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
31.84
31.84
3.07
2.55
0.22
0.12
0.0
10.49
Abbott Laboratories
Abbott Laboratories
33.76
33.76
18.76
4.11
0.14
0.06
0.02
21.42
Medtronic Plc
Medtronic Plc
29.69
29.69
3.04
5.28
0.07
0.04
0.03
38.47
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc
Buy
$80.6M
-97.51%
NA
0.0%
Stryker Corporation
Stryker Corporation
Buy
$108.3B
62.3%
40.29
13.92%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$79.0B
38.82%
89.95
6.81%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$43.7B
24.13%
31.84
24.56%
Abbott Laboratories
Abbott Laboratories
Buy
$171.7B
35.94%
33.76
12.83%
Medtronic Plc
Medtronic Plc
Buy
$107.1B
-18.92%
29.69
11.47%

Institutional Holdings

  • Hovey Youngman Associates Inc

    7.13%

  • Vanguard Group Inc

    2.00%

  • Birchview Capital, LP

    1.57%

  • Oracle Investment Management Inc

    1.05%

  • Alyeska Investment Group, L.P.

    0.86%

  • BlackRock Inc

    0.45%

Corporate Announcements

  • Accelerate Diagnostics Inc Earnings

    Accelerate Diagnostics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Organization
Accelerate Diagnostics Inc
Employees
179
CEO
Mr. Jack Phillips
Industry
Health Technology

Discover More

FAQs